1104.8000 4.60 (0.42%)
NSE Sep 22, 2025 09:52 AM
Volume: 29,997
 

1104.80
0.42%
Prabhudas Lilladhar
We reduce earnings estimate of JUBILANT by 23%17.5%11.6% for FY21/22/23E due to weak and inconsistent performance of its Pharmaceutical segment (65% revenue and 78% EBITDA contribution in FY20) whose key contributors Radio pharma and Allergy are currently witnessing lower volumes caused by pandemic in US. Radiopharma being a hospital driven...
Jubilant Pharmova Ltd. has gained 22.37% in the last 6 Months
More from Jubilant Pharmova Ltd.
Recommended